The metabolism of Buprenorphine can be decreased when combined with Rabeprazole. Desflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Methadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Verapamil. Pethidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Piritramide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Barbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Ketazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Benzphetamine may increase the analgesic activities of Buprenorphine. Buprenorphine may increase the serotonergic activities of Indalpine. Buprenorphine may increase the serotonergic activities of Dapoxetine. Prochlorperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Fluvastatin. Orphenadrine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Pheniprazine. Lofentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Fluconazole. The metabolism of Buprenorphine can be decreased when combined with Venlafaxine. Isoflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Minocycline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Metolazone. The risk or severity of adverse effects can be increased when Metixene is combined with Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Fosamprenavir. Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Delavirdine. The serum concentration of Buprenorphine can be increased when it is combined with Ombitasvir. The metabolism of Buprenorphine can be increased when combined with Rifampicin. Eszopiclone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Buprenorphine may increase the constipating activities of Ramosetron. Buprenorphine may increase the serotonergic activities of Milnacipran. The risk or severity of adverse effects can be increased when Biperiden is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Pergolide is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Benactyzine is combined with Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Lapatinib. Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Chloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Buprenorphine. Dextroamphetamine may increase the analgesic activities of Buprenorphine. Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Quinine. Lithium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Ticagrelor. Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Pivhydrazine. clomethiazole may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Methscopolamine is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Eplerenone. Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Fluorouracil. The serum concentration of Buprenorphine can be increased when it is combined with Darunavir. The serum concentration of Naloxegol can be increased when it is combined with Buprenorphine. Prazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Cocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Benzatropine is combined with Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Itraconazole. Buprenorphine may increase the serotonergic activities of Zimelidine. Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Ketobemidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Toloxatone. The risk or severity of adverse effects can be increased when Methantheline is combined with Buprenorphine. The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Buprenorphine resulting in a loss in efficacy. The serum concentration of Pravastatin can be increased when it is combined with Buprenorphine. Topiramate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Cicletanine. Nortriptyline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Clarithromycin. The metabolism of Buprenorphine can be decreased when combined with Citalopram. Alimemazine may increase the hypotensive activities of Buprenorphine. The risk or severity of adverse effects can be increased when Lisuride is combined with Buprenorphine. Buprenorphine may increase the serotonergic activities of Levomilnacipran. Tandospirone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Eliglustat. The metabolism of Buprenorphine can be decreased when combined with Telaprevir. Gabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Clotrimazole. The serum concentration of Rosuvastatin can be increased when it is combined with Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Sulfisoxazole. The serum concentration of Pitavastatin can be increased when it is combined with Buprenorphine. Oxethazaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium. Amphetamine may increase the analgesic activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Caroxazone. The metabolism of Buprenorphine can be decreased when combined with Gemfibrozil. The serum concentration of Mevastatin can be increased when it is combined with Buprenorphine. Cyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Mersalyl. Methylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Darifenacin. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Iproniazid. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Pargyline. The serum concentration of Buprenorphine can be increased when it is combined with Luliconazole. The metabolism of Buprenorphine can be decreased when combined with Lorcaserin. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Quinethazone. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Moclobemide. BL-1020 may increase the hypotensive activities of Buprenorphine. Clemastine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Fluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Carfentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Zuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Cholecalciferol. Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Halothane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Midostaurin. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Mebanazine. The metabolism of Buprenorphine can be decreased when combined with Irbesartan. The risk or severity of adverse effects can be increased when Methylergometrine is combined with Buprenorphine. Temazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Hydrochlorothiazide. The risk or severity of adverse effects can be increased when Pentolinium is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Trimethaphan is combined with Buprenorphine. Methadone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Azelastine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Thioproperazine may increase the hypotensive activities of Buprenorphine. Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Buprenorphine may decrease the analgesic activities of Bezitramide. The metabolism of Buprenorphine can be decreased when combined with Lumefantrine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorothiazide. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Amiloride. Hexobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Flibanserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Tetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Cyclothiazide. The risk or severity of adverse effects can be increased when Pipecuronium is combined with Buprenorphine. Alprazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Buprenorphine. Methsuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.